Biomarker Research in ADHD: the Impact of Nutrition (BRAIN) - study protocol of an open-label trial to investigate the mechanisms underlying the effects of a few-foods diet on ADHD symptoms in children

• Published in: BMJ open 2019-11, Vol.9 (11), p.e029422-e029422
• Main Authors: Stobernack, Tim, de Vries, Stefan P W, Rodrigues Pereira, Rob, Pelsser, Lidy M, ter Braak, Cajo J F, Aarts, Esther, van Baarlen, Peter, Kleerebezem, Michiel, Frankena, Klaas, Hontelez, Saartje
• Format: Article
• Language: English
• Subjects: Attention deficit hyperactivity disorder; Biomarkers; Child & adolescent psychiatry; Clinical trials; Hyperactivity; Mental Health; Pediatrics; Well being
• ISSN: 2044-6055; 2044-6055
• DOI: 10.1136/bmjopen-2019-029422

IntroductionAttention deficit hyperactivity disorder (ADHD) is the most common childhood behavioural disorder, causing significant impediment to a child’s development. It is a complex disorder with numerous contributing (epi)genetic and environmental factors. Currently, treatment consists of behavioural and pharmacological therapy. However, ADHD medication is associated with several side effects, and concerns about long-term effects and efficacy exist. Therefore, there is considerable interest in the development of alternative treatment options. Double-blind research investigating the effects of a few-foods diet (FFD) has demonstrated a significant decrease in ADHD symptoms following an FFD. However, an FFD requires a considerable effort of both child and parents, limiting its applicability as a general ADHD treatment. To make FFD intervention less challenging or potentially obsolete, we need to understand how, and in which children, an FFD affects ADHD behaviour and, consequently, the child’s well-being. We hypothesise that an FFD affects brain function, and that the nutritional impact on ADHD is effectuated by a complex interplay between the microbiota, gut and brain, that is, the microbiota–gut–brain axis.Methods and analysisThe Biomarker Research in ADHD: the Impact of Nutrition (BRAIN) study is an open-label trial with researchers blinded to changes in ADHD symptoms during sample processing and initial data analyses.Ethics and disseminationThe Medical Research and Ethics Committee of Wageningen University has approved this study (NL63851.081.17, application 17/24). Results will be disseminated through peer-reviewed journal publications, conference presentations, (social) media and the BRAIN study website. A summary of the findings will be provided to the participants.Trial registration numberNCT03440346.Study datesCollection of primary outcome data started in March 2018 and will be ongoing until 100 children have participated in the study. Sample data analysis will start after all samples have been collected.